Thread by @Biotech2k1

Been Working on my Science Categories:

Pathways 20% max
Synthetic Lethality 15% max
CRISPR 15% max
Protein Degraders 15% max
Cell Therapies 15% max
Delivery 15% max
Max 95% with 5% cash

I think come out to a good diversification. It would never get that low on cash as I plan a few transitions. I am splitting up Pathways and Synthetic Lethality which is kind of a judgement call since they highly overlap.

Pathways:
1 $BPMC max 5% = 3.3%
2. $TPTX max 5% = 3.3%
3. $RVMD max 3% = 2%
4. $ERAS max 3% = .67%
5. $RLAY max 3% = 2%
Max 19%

Synthetic Lethality:
1. $MRTX max 5% = 3.3%
2. $SDGR max 3% = 1.35%
3. $RPTX max 3% = 2%
Max 11%

CRISPR:
1. $NTLA max 3% = 0% above $125
2. $CRSP max 3% = 0% above $100
3. $BEAM max 3% = 0% above $83
4. $CRBU max 3% = 2%
Max 12%

Cell Therapies:
1. $FATE max 3% = 0% above $50
2. $SANA max 3% = 1.35%
3. $IPSC max 3% = 1.35%
4. $TIL max 3% = 1.35%
5. $CABA max 3% = 1.35%
Max 15%

Delivery:
1. $GBIO reduce to 0% = 2.7%
2. $FDMT reduce to 0% = 2%
Max reduce to 0%

This is just where I would like to go. Many of these companies I don't own as they are grossly overvalued. Some I would fade as the sector continues to go higher as its so over value for the $XBI in general.